心房颤动抗凝治疗的研究进展

传统的抗凝药物(华法林)作为心房颤动(房颤)患者唯一的抗凝药物达50年之久,其抗凝效果虽已受到医学界广泛的肯定,但同时存在出血风险高、治疗窗狭窄、需要长期监测患者国际标准化比率以调整药量等缺点;导致患者依从性差,临床应用上亦受到限制。因此,推动了世界各国对新型口服抗凝剂的积极研发,以满足临床治疗的需求。该文将对房颤抗凝治疗的研究进展予以综述。

Research Progress in Anticoagulant Treatment for Atrial Fibrillation

The traditional anticoagulant （Warfarin） has been the only anticoagulant for patients with atrial fibrillation for 50 years and proven effective. However, the high risk of bleeding, narrow therapeutic window,long term INR monitoring for proper adjustment of medication, etc. are the major drawbacks of this medicine, leading to poor compliances of patients and restrictions on clinical applications. Thus, the development of a series of new oral anticoagulants （NOAC） is motivated,in order to meet the satisfaction of clinical practices. Here is to make a review of the research progress of anticoagulant treatment for atrial fibrillation.